353 related articles for article (PubMed ID: 34425858)
21. Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Kusano Y; Yokoyama M; Inoue N; Yamauchi H; Takahashi A; Tsuyama N; Mishima Y; Nishimura N; Takeuchi K; Terui Y; Hatake K
Ann Hematol; 2018 Feb; 97(2):289-297. PubMed ID: 29138885
[TBL] [Abstract][Full Text] [Related]
22. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
[TBL] [Abstract][Full Text] [Related]
25. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
26. [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
Xiong W; Yi S; Li H; Liu H; Li Z; Lü R; Liu W; Zou D; Qiu L
Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(44):3593-7. PubMed ID: 26813371
[TBL] [Abstract][Full Text] [Related]
27. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
[TBL] [Abstract][Full Text] [Related]
29. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
[TBL] [Abstract][Full Text] [Related]
30. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
31. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482
[TBL] [Abstract][Full Text] [Related]
32. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
33. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
[TBL] [Abstract][Full Text] [Related]
34. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
[TBL] [Abstract][Full Text] [Related]
35. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
36. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
van Oers MH; Klasa R; Marcus RE; Wolf M; Kimby E; Gascoyne RD; Jack A; Van't Veer M; Vranovsky A; Holte H; van Glabbeke M; Teodorovic I; Rozewicz C; Hagenbeek A
Blood; 2006 Nov; 108(10):3295-301. PubMed ID: 16873669
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Zohren F; Bruns I; Pechtel S; Schroeder T; Fenk R; Czibere A; Maschmeyer G; Kofahl-Krause D; Niederle N; Heil G; Losem C; Welslau M; Brugger W; Germing U; Kronenwett R; Barth J; Rummel MJ; Haas R; Kobbe G
Blood; 2015 Sep; 126(12):1407-14. PubMed ID: 26239087
[TBL] [Abstract][Full Text] [Related]
38. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
39. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
[TBL] [Abstract][Full Text] [Related]
40. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
